Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT02312882
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
Eugene and Gloria Bauer Professor
Clinical Professor, Dermatology
Inclusion Criteria:
- Age >= 18 years old
- Diagnosis of alopecia areata with >50% scalp involvement, alopecia totalis, or
alopecia universalis
- Hair loss present for at least 6 months
- No treatment for alopecia areata in past 2 months
- No evidence of hair regrowth
- Females of childbearing potential must use birth control while taking the medication
and there must be a negative pregnancy test documented prior to starting the
medication
- Fluent in spoken and written English
Exclusion Criteria:
- Age <18 years old
- Patients have received treatment known to affect alopecia areata within 2 months of
enrolling in the study
- Patients with a history of malignancy (except history of successfully treated basal
cell or squamous cell carcinoma of the skin)
- Patients known to be HIV or hepatitis B or C positive
- Patients with positive tuberculin skin test or positive QuantiFERON TB test
- Patients with leukopenia or anemia
- Patients with renal or hepatic impairment
- Patients with peptic ulcer disease
- Patients taking immunosuppressive medications, including but not limited to
prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus,
cyclosporine, or TNH-alpha inhibitors
- Women of childbearing potential who are unable or unwilling to use birth control while
taking the medication
- Women who are pregnant or nursing
drug: Tofacitinib
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michelle Kim